The Express Influenza A+B Test
MetadataShow full item record
We propose a business model based on the application of new antibody technologies that will revolutionize rapid disease diagnostics. Currently, rapid diagnostic tests rely on the production of monoclonal antibodies that require expensive hybridoma cell culture systems for their production. We plan to significantly reduce production costs by generating antibodies in cheap bacterial expression systems. In addition, we will modify our antibodies to enhance their performance relative to monoclonal antibodies. The result will be a product that is designed to outperform traditional monoclonal antibody-based rapid diagnostics, at a fraction of the cost. These advantages will ensure that PathogeniX diagnostic tests are affordable, rapid, and reliable. Development and marketing of PathogeniX's first product, FluCheck, will aid in the diagnosis of the globally relevant pathogen, influenza, and establish PathogeniX as a leader in rapid diagnostics technology.